Inclusion Criteria:

1. Male 30 to 70 years (inclusive)

2. Metabolic syndrome defined according to the International Diabetes Foundation (IDF):

   1. Abdominal obesity (waist circumference > 94 cm for European men) and any two of the following criteria
   2. Triglycerides > 1.7 mmol/L or specific treatment for this
   3. HDL < 1.03 nmol/L or specific therapy for this
   4. Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg or treatment for this.
   5. Fasting plasma glucose ≥ 5.6 mmol/L (venous glucose ≥ 6.1 mmol/L) or previously diagnosed type 2 diabetes mellitus defined by: Fasting plasma glucose ≥ 7.8 mmol/L on two occasions, or random glucose ≥ 11.1 mmol/L and classic symptoms of type 2 diabetes
3. Impaired glucose tolerance If the definition of the metabolic syndrome, as described above, is fulfilled but fasting plasma glucose ≤ 5.6 mmol/L (fasting venous glucose is < 6.1 mmol/L) the result of an oral glucose tolerance test must be classified as reduced glucose tolerance with a venous blood glucose 7.8 - 11.1 mmol/L or higher 120 min after intake of 75 g of glucose in a water solution (2h OGTT) (www.diabetes.org/main/info/pre-diabetes.jsp)
4. Hypogonadism, S-Testosterone <12 nmol/L taken at 7:00-10:00 a.m. Sample taken less than 2 months before inclusion in the study.
5. Screening value of HbA1c <7.5 %
6. Weight < 110 kg
7. Body Mass Index (BMI) < 35
8. Hematocrit < 50%
9. Signed Written informed consent obtained -

Exclusion Criteria:

1. Ongoing pharmacological treatment of type 2 diabetes except for metformin.
2. Use of androgen therapy or anabolic steroids within 6 months of entry into the study.
3. Known congestive heart failure, progressing angina pectoris or a history of myocardial infarction within the last 12 months.
4. Known untreated pituitary disease.
5. A history of significant renal or liver disease or any malignancy.
6. Use of drugs interfering with androgens; spironolactone, Ketoconazol, corticosteroids, cimetidine, fentiazines, tricyclic antidepressants, anabolic steroids, 5-alfa reductase inhibitors, antiestrogens.
7. Prostate Specific Antigen (PSA) > 4 ng/ml.
8. Suspected malignancy after prostata palpation, unless biopsy shows the opposite.
9. Malignant tumour of the mammary gland
10. Ongoing micturition problem severely affecting patient's daily living as judged by the investigator.
11. Any contraindication for treatment with testosterone 1% hydroalchol gel according to the labelling as well as known or suspected allergy to the specific product used in the study.
12. Contagious blood disease.
13. Known alcohol or drug abuse, or any condition associated with poor compliance.
14. Participation in a clinical study during the last 90 days before start of treatment.
15. Previous enrolment or randomisation in the present study -